Trial Profile
Rosiglitazone-induced weight gain
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 18 Oct 2016 Status changed from recruiting to discontinued due to published data on Rosiglitazone.
- 19 Nov 2006 New trial record.